Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting β2‐agonists: addition of montelukast in an open-label pilot study

References

• Busse WW. Inflammation in asthma: the cornerstone of the disease and the target of the therapy. J Allergy Clin Immunol 1998;102:S17–22
   PubMed Web of Science ®Google Scholar
• Lazarus SC. Inflammation, inflammatory mediators, and mediator antagonists in asthma. J Clin Pharmacol 1998;38:77–82
   Google Scholar
• Hamid Q, Tuli MK, Liu MC, et al. Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol 2003;111:S5–12
   PubMedGoogle Scholar
• Szefler SJ. The natural history of asthma and early intervention. J Allergy Clin Immunol 2002;109:S549–53
   PubMed Web of Science ®Google Scholar
• Vignola AM, Mirabella F, Costanzo G, et al. Airway remodeling in asthma. Chest 2003;123:417S–22
   Google Scholar
• Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc 2003;24:79–83
   PubMed Web of Science ®Google Scholar
• Lemanske Jr RF, Busse WW. Asthma. J Allergy Clin Immunol 2003;111:S502–19
   PubMedGoogle Scholar
• British Guideline on the Management of Asthma: A national clinical guidelines. British Thoracic Society and Scottish Intercollegiate Guidelines Network. Revised edition April 2004 [online]. Available from http://www.brit-thoracic.org.uk/sign/%20index.htm [last accessed 14 April 2005]
   Google Scholar
• National Institutes of Health, National Heart, Lung, and Blood Institute. Asthma management, and prevention. Global initiative for asthma. A practical guide for public health officials, and health care professionals. Based on the global strategy for asthma management and prevention NHLBI/WHO workshop report. Bethesda, MD: NIH, 1995. (NIH publication No. 96–3659A.) Updated report October 2004
   Google Scholar
• Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised cooperative trial. BMJ 2003;327:891–5
   PubMed Web of Science ®Google Scholar
• Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211–6
   PubMed Web of Science ®Google Scholar
• Vaquerizo MJ, Casan P, Castillo J, et al. CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204–10
   Google Scholar
• El-Radhi AS, Hogg CL, Bungre JK, et al. Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 2000;83:158–62
   Google Scholar
• Thomas PS. Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol 2001; 79:132–40
   PubMed Web of Science ®Google Scholar
• Mitsuta K, Matsuse H, Fukushima C, et al. Production of TNF-alpha by peripheral blood mononuclear cells through activation of nuclear factor kappa B by specific allergen stimulation in patients with atopic asthma. Allergy Asthma Proc 2003;24:19–26
   PubMed Web of Science ®Google Scholar
• Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110:728–35
   PubMed Web of Science ®Google Scholar
• Bjermer L, Diamant Z. Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. Treat Respir Med 2004;3:235–46
   PubMedGoogle Scholar
• Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531–8
   PubMed Web of Science ®Google Scholar
• Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953–9
   PubMed Web of Science ®Google Scholar
• Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197–206
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57–62
   PubMed Web of Science ®Google Scholar
• Holgate ST, Peters-Golden M, Panettieri RA, et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111: S18–34
   PubMedGoogle Scholar
• Nayak A. A review of montelukast in the treatment of asthma and allergic rhinitis. Expert Opin Pharmacother 2004;5:679–86
   PubMed Web of Science ®Google Scholar
• Ram FSF, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. The Cochrane Database Syst Rev 2005;CD003137
   Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al., for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44
   Google Scholar
• Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Grit Care Med 2003;167:1232–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Resp J 1999;14:902–7
   PubMed Web of Science ®Google Scholar
• Remington TL, DiGiovine B. Long-acting beta agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Op Pulm Med 2005;11:74–8
   PubMed Web of Science ®Google Scholar
• Juniper EF, O'Byrne PM, Ferrie PJ, et al. Measuring asthma control. Clinic questionnaire or daily diary? AmJ Respir Grit Care Med 2000;162:1330–4
   PubMed Web of Science ®Google Scholar
• Rosias PP, Dompeling E, Dentener MA, et al. Childhood asthma: exhaled markers of airway inflammation, asthma control score, and lung function tests. Pediatr Pulmonol 2004;38:107–14
   PubMed Web of Science ®Google Scholar
• Leynaert B, Neulcirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106:S201–5
   PubMed Web of Science ®Google Scholar
• Bousquet J, Van Cauwenberge P, Khaltaev N. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147–334
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549–58
   PubMed Web of Science ®Google Scholar
• van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast Fall RhinitisStudy Group. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268–76
   Google Scholar